Published in Contemp Clin Trials on December 31, 2013
Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE) | NCT01077310
Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care (2014) 0.93
Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep (2014) 0.87
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend (2015) 0.82
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials (2014) 0.81
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abuse Treat (2014) 0.79
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. Transl Psychiatry (2015) 0.77
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend (2017) 0.75
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug Alcohol Depend (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction (1993) 41.55
The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat (1992) 29.45
The Brief Symptom Inventory: an introductory report. Psychol Med (1983) 22.83
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15
Release from prison--a high risk of death for former inmates. N Engl J Med (2007) 12.46
Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol (1997) 11.33
The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health (2002) 8.17
Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis (2004) 6.27
Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res (1993) 5.01
HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One (2009) 4.69
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 4.64
The method of minimization for allocation to clinical trials. a review. Control Clin Trials (2002) 4.23
Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr (2006) 2.72
SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull (1986) 2.46
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend (2010) 2.38
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry (1996) 2.22
Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train (2008) 2.18
Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr (2006) 2.12
Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis (2011) 2.12
Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction (2004) 1.88
PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol (2006) 1.58
DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. Eur Psychiatry (1998) 1.52
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse (2010) 1.48
Consistency of self-administered and interview-based Addiction Severity Index composite scores. Addiction (2000) 1.46
Reliability and validity of the alcohol short index of problems and a newly constructed drug short index of problems. J Stud Alcohol Drugs (2009) 1.45
Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol (2007) 1.42
Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol (2007) 1.42
Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health (2003) 1.38
Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin Exp Res (2011) 1.33
A randomised controlled trial comparing computer-assisted with face-to-face sexual history taking in a clinical setting. Sex Transm Infect (2006) 1.27
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol (2012) 1.24
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl (2005) 1.19
Phosphatidylethanol and alcohol consumption in reproductive age women. Alcohol Clin Exp Res (2009) 1.19
Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports. Addict Biol (2010) 1.15
Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol (2002) 1.13
Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction (2008) 1.12
Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav (2013) 1.09
Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav (2013) 1.07
Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care (2013) 1.04
Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl (2005) 1.02
Screening for drug and alcohol use disorders and their association with HIV-related sexual risk behaviors among men who have sex with men in Peru. PLoS One (2013) 1.00
Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One (2013) 1.00
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials (2011) 0.99
A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment. Drug Alcohol Depend (2013) 0.98
Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviors among men who have sex with men in Peru. AIDS Behav (2014) 0.94
Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment. Addict Behav (1992) 0.93
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res (2008) 0.90
Computerized assessment facilitates disclosure of sensitive HIV risk behaviors among African Americans entering substance abuse treatment. Am J Drug Alcohol Abuse (2012) 0.83
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials (2014) 0.81
Corrigendum to "Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community" [Contemp. Clin. Trials (2014) 209-218]. Contemp Clin Trials (2017) 0.75